DNA Biomed Solns (TA:DNA) — Market Cap & Net Worth
Market Cap & Net Worth: DNA Biomed Solns (DNA)
DNA Biomed Solns (TA:DNA) has a market capitalization of $32.49 Million (ILA12.12 Billion) as of July 22, 2026. Listed on the TA stock exchange, this Israel-based company holds position #23458 globally and #326 in its home market, demonstrating a -11.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DNA Biomed Solns's stock price ILA98.40 by its total outstanding shares 123164100 (123.16 Million). Review how much free cash does DNA Biomed Solns generate to assess how much free cash flow the company generates relative to operating cash flow.
DNA Biomed Solns Market Cap History: 2015 to 2026
DNA Biomed Solns's market capitalization history from 2015 to 2026. Data shows change from $369.69 Million to $32.49 Million (-22.76% CAGR).
DNA Biomed Solns Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DNA Biomed Solns's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
99.49x
DNA Biomed Solns's market cap is 99.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.38x
DNA Biomed Solns's market cap is 1.38 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $24.24 Million | $560.00K | -$23.54 Million | 43.28x | N/A |
| 2023 | $20.87 Million | $306.00K | -$1.18 Million | 68.20x | N/A |
| 2024 | $30.44 Million | $306.00K | $22.10 Million | 99.49x | 1.38x |
Competitor Companies of DNA by Market Capitalization
Companies near DNA Biomed Solns in the global market cap rankings as of July 22, 2026.
Key companies related to DNA Biomed Solns by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #560 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $480.50 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $672.15 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €753.60 |
| #560 | UCB SA | BR:UCB | $47.34 Billion | €238.00 |
DNA Biomed Solns Historical Marketcap From 2015 to 2026
Between 2015 and today, DNA Biomed Solns's market cap moved from $369.69 Million to $ 32.49 Million, with a yearly change of -22.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA32.49 Million | -1.60% |
| 2025 | ILA33.02 Million | +8.46% |
| 2024 | ILA30.44 Million | +45.89% |
| 2023 | ILA20.87 Million | -13.90% |
| 2022 | ILA24.24 Million | -53.51% |
| 2021 | ILA52.14 Million | +112.52% |
| 2020 | ILA24.53 Million | +6.29% |
| 2019 | ILA23.08 Million | -91.37% |
| 2018 | ILA267.46 Million | -51.82% |
| 2017 | ILA555.13 Million | +28.65% |
| 2016 | ILA431.50 Million | +16.72% |
| 2015 | ILA369.69 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of DNA Biomed Solns was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.49 Million USD |
| MoneyControl | $32.49 Million USD |
| MarketWatch | $32.49 Million USD |
| marketcap.company | $32.49 Million USD |
| Reuters | $32.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more